Curated News
By: NewsRamp Editorial Staff
August 20, 2026
Onco-Innovations and Ifowonco Join Forces to Develop Oral LAG-3 Inhibitors for Cancer
TLDR
- Onco-Innovations secures exclusive option on oral LAG-3 inhibitors, potentially gaining a competitive edge in next-gen cancer immunotherapy.
- Onco-Innovations signs LOI with Ifowonco to evaluate oral small-molecule LAG-3 inhibitors, combining with DDR therapeutics like ONC010 for solid tumors.
- This collaboration aims to enhance anti-tumor immune responses, offering hope for more effective and accessible cancer treatments.
- Oral LAG-3 inhibitors could replace IV monoclonal antibodies, making immunotherapy more convenient for patients.
Impact - Why it Matters
This collaboration between Onco-Innovations and Ifowonco could revolutionize cancer treatment by combining two cutting-edge approaches: DDR inhibition and LAG-3 blockade. If successful, this oral small-molecule therapy could provide a more convenient alternative to current intravenous monoclonal antibodies, potentially improving patient outcomes and quality of life. For investors, this strategic move positions Onco-Innovations at the forefront of next-generation cancer immunotherapy, offering significant growth potential as the company expands its pipeline and tackles solid tumours more effectively.
Summary
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has taken a significant step forward in its mission to advance cancer treatment by signing a non-binding letter of intent (LOI) with Ifowonco Informatics Incorporated. The agreement, which is the first step toward a definitive deal, would grant Onco an exclusive option to Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (LAG-3). This collaboration aims to combine Ifowonco's oral small-molecule immune checkpoint technology with Onco's expertise in DNA damage response (DDR) therapeutics, translational oncology, and clinical development. The companies believe that combining DDR inhibition with LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications, marking a novel approach in cancer immunotherapy.
Ifowonco's program focuses on developing orally available small-molecule LAG-3 inhibitors, a departure from currently approved LAG-3 therapies that are administered intravenously as monoclonal antibodies. This oral formulation could offer greater convenience and potentially improved patient compliance. The companies intend to evaluate the LAG-3 program independently and, where supported by preclinical findings, explore its use alongside DDR-based therapeutic approaches, including Onco's ONC010 program. Thomas O'Shaughnessy, CEO of Onco-Innovations, expressed optimism, stating that the potential agreement could position the company "at the intersection of precision oncology and next-generation cancer immunotherapy." This strategic move underscores Onco's commitment to pioneering innovative solutions in oncology, building on its exclusive worldwide license to patented technology targeting solid tumours.
For more details, the full press release is available at https://ibn.fm/E63Ne. Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, and this collaboration with Ifowonco represents a promising advancement in the fight against cancer. Investors and stakeholders can stay updated with the latest news on ONNVF at https://ibn.fm/ONNVF. BioMedWire, a specialized communications platform for the biotech and life sciences sectors, disseminated this news, highlighting its significance in the industry.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Onco-Innovations and Ifowonco Join Forces to Develop Oral LAG-3 Inhibitors for Cancer
